4//SEC Filing
Xu Stella 4
Accession 0001209191-21-024234
CIK 0001807120other
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 6:19 PM ET
Size
13.7 KB
Accession
0001209191-21-024234
Insider Transaction Report
Form 4
Xu Stella
Director10% Owner
Transactions
- Conversion
Series A Preferred Stock
2021-03-30−7,236,938→ 0 total(indirect: See footnote)→ Common Stock (4,439,839 underlying) - Conversion
Series B Preferred Stock
2021-03-30−458,016→ 0 total(indirect: See footnote)→ Common Stock (280,991 underlying) - Conversion
Common Stock
2021-03-30+4,439,839→ 4,439,839 total(indirect: See footnote) - Purchase
Common Stock
2021-03-30$20.00/sh+10,000$200,000→ 4,730,830 total(indirect: By Spouse) - Conversion
Common Stock
2021-03-30+280,991→ 4,720,830 total(indirect: See footnote)
Footnotes (3)
- [F1]All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.
- [F2]The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest.
- [F3]The shares were purchased in the Issuer's initial public offering.
Documents
Issuer
Design Therapeutics, Inc.
CIK 0001807120
Entity typeother
Related Parties
1- filerCIK 0001728741
Filing Metadata
- Form type
- 4
- Filed
- Mar 31, 8:00 PM ET
- Accepted
- Apr 1, 6:19 PM ET
- Size
- 13.7 KB